Rare mutations are helping dangerous hospital bacteria slip past the last-line antibiotic defense
Another last-resort antibiotic has fallen victim to the rapid evolution of drug-resistant superbugs. The powerful antibiotic combination ceftazidime-avibactam (CZA), widely used to treat severe hospital-acquired infections caused by Pseudomonas aeruginosa—particularly in critically ill and immunocom...
July 16, 20266 views
Image: Phys.org
Another last-resort antibiotic has fallen victim to the rapid evolution of drug-resistant superbugs. The powerful antibiotic combination ceftazidime-avibactam (CZA), widely used to treat severe hospital-acquired infections caused by Pseudomonas aeruginosa—particularly in critically ill and immunocompromised patients—can no longer eliminate some of these infections.
Be the first to receive the latest news, market analysis and updates — delivered straight to your inbox.
We value your privacy
We use cookies to run this site and, with your consent, to measure
traffic and improve our content. Necessary cookies are always on. You
can accept all cookies or choose which ones to allow.
Privacy policy.